Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.

NCT06611371 is registered in ClinicalTrials.gov with Inventprise Inc. as lead sponsor.

NCT NCT06611371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06611371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.
Lead sponsor
Inventprise Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 12, 2024
Completion date
February 28, 2026
Enrollment
600 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

group b streptococcal infections